AgingResearch.NewsJoin free

TaiGen Biotechnology

CompanyTaiwanFounded 2005

Wikidata

TaiGen Biotechnology develops one asset, in phase 1 (ISM4808 in anaemia of chronic kidney disease). Mostly small molecule acting on EGLN1 and EGLN2; based in Taiwan, founded in 2005.

1
Asset
Furthest stage
Phase 1
0
Trials
1
Signal

Pipeline

1

  • ISM4808

    Oral PHD1/2 inhibitor that raises the body's own erythropoietin and improves iron use

    Phase 1, Small molecule, EGLN1, EGLN2, anaemia of chronic kidney disease, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Signals1
  • Similar companies1

Intelligence